WT | + Metformin | Cav-1−/− | + Metformin | |
---|---|---|---|---|
Phe max (10−5 M) | ||||
Contraction (g) | 0.94 ± 0.15 | 0.65 ± 0.07 | 0.40 ± 0.10* | 0.42 ± 0.07* |
+ l-NAME (3 × 10−4 M) | 1.21 ± 0.14 | 0.64 ± 0.11# | 0.69 ± 0.10* | 0.64 ± 0.10 |
+ODQ (10−5 M) | 1.10 ± 0.16 | 1.31 ± 0.17† | 0.89 ± 0.13† | 0.76 ± 0.13† |
− Endo | 1.05 ± 0.19 | 0.58 ± 0.08# | 0.72 ± 0.11† | 0.54 ± 0.07 |
Phe pED50 (-log M) | 7.11 ± 0.18 | 7.00 ± 0.10 | 6.66 ± 0.13 | 7.47 ± 0.10*# |
+l-NAME | 7.36 ± 0.17 | 7.36 ± 0.14 | 6.91 ± 0.18 | 7.03 ± 0.14 |
+ODQ | 7.43 ± 0.14 | 7.53 ± 0.10† | 7.05 ± 0.10*† | 7.10 ± 0.09* |
− Endo | 7.36 ± 0.16 | 7.36 ± 0.13† | 6.94 ± 0.13 | 7.07 ± 0.11 |
KCl contraction (g) | 0.70 ± 0.04 | 0.51 ± 0.05# | 0.47 ± 0.05* | 0.42 ± 0.04 |
-Endo | 0.65 ± 0.06 | 0.42 ± 0.06# | 0.37 ± 0.04* | 0.45 ± 0.06 |
Phe max contraction | ||||
(% 96 mM KCl) | 141.18 ± 20.46 | 133.83 ± 7.39 | 108.43 ± 23.30 | 111.46 ± 17.93 |
+l-NAME | 186.21 ± 22.88 | 176.26 ± 22.35 | 206.67 ± 38.31† | 156.58 ± 21.08 |
+ODQ | 166.76 ± 20.95 | 202.41 ± 8.24† | 188.93 ± 19.56† | 187.41 ± 27.87† |
- Endo | 161.98 ± 19.75 | 145.55 ± 15.54 | 223.32 ± 42.08† | 131.62 ± 15.59# |
ACh (10−5 M) % relaxation | 23.51 ± 5.33 | 24.36 ± 5.63 | 85.20 ± 8.15* | 64.36 ± 5.74*# |
pED50 (-log M) | 6.32 ± 0.14 | 6.23 ± 0.13 | 7.45 ± 0.27* | 6.70 ± 0.11*# |
SNP (10−8 M) % relaxation | 57.66 ± 4.60 | 53.03 ± 7.59 | 73.75 ± 4.93* | 50.08 ± 5.11# |
pED50 (−log M) | 8.12 ± 0.09 | 8.08 ± 0.13 | 8.52 ± 0.09* | 7.98 ± 0.15# |
↵* Measurements in cav-1−/− are significantly different (P < 0.05) from corresponding measurements in WT.
↵# Measurements in metformin-treated mice are significantly different (P < 0.05) from corresponding measurements in mice without metformin treatment.
↵† Measurements in l-NAME or ODQ-treated or endothelium-denuded arteries are significantly different from corresponding measurements in control nontreated arteries.